Ummino to launch precision fermentation lactosamine in US adult gut market
Ummino will launch its human milk oligosaccharide (HMO) compound, lactosamine, produced via precision fermentation, targeting the adult gut health market in the US. This B2B strategy, backed by significant investment, signals a new competitive front in prebiotics.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Raleigh, United States — 19 March 2026
Ummino, a biosciences start-up established in 2020, is poised to introduce lactosamine, a human milk oligosaccharide (HMO) found in breastmilk, into the US adult gut health market. This compound, named Hummino, is produced through precision fermentation, a high-yield, scalable manufacturing process. Leveraging research primarily from NC State University, Ummino aims to address adult microbiome stability and gut barrier function, signalling a strategic shift from traditional infant nutrition applications for HMOs. The company's initial focus is the B2B ingredient supply, foregoing direct-to-consumer sales in favour of partnerships with existing supplement manufacturers and brand owners.
Ummino's CEO, Charles Dykes, stressed the importance of simplifying complex scientific benefits for commercial partners, a critical factor for market adoption. The company has secured significant backing from investors, including Siddhi Capital and Danone Ventures, underscoring both financial confidence and strategic industry alignment for their novel prebiotic. This capital injection will support manufacturing scale-up, and market penetration, initially within the United States, with subsequent plans for cross-market expansion. The precision fermentation method offers a more sustainable and cost-effective route to producing complex biomolecules like lactosamine, compared to earlier synthesis methods or extraction from biological sources.
The commercialisation of Hummino positions Ummino directly within the expanding prebiotic market, which has seen substantial growth driven by consumer interest in gut health. The strategic choice to target adult formulations with a breastmilk-derived compound opens new avenues for product innovation beyond established probiotic and fibre-based prebiotic categories. Manufacturers must now consider integrating such advanced ingredients to maintain a competitive edge, particularly as consumer awareness of HMO benefits transitions from infant formula to broader wellness applications.
What this means for United States
US brand owners face a new imperative to evaluate advanced prebiotic ingredients like Ummino's lactosamine to maintain market relevance in the rapidly evolving gut health sector. Competitors leveraging traditional prebiotics may experience margin compression unless they innovate. Regulatory teams must monitor FDA guidance on novel fermentation-derived ingredients, specifically their GRAS status and labelling implications for HMOs in adult formulations. Procurement leads should engage with Ummino to understand MOQs, lead times, and pricing as early as Q4 2026. Early adoption presents an opportunity for product differentiation and premium positioning, potentially capturing market share from less sophisticated prebiotic offerings.
The B2B model allows Ummino to rapidly scale its ingredient supply, making it accessible to a wider array of formulators who might otherwise shy away from developing such complex compounds in-house. This development is set to intensify competition within the functional ingredients space, pushing established players to accelerate their R&D into novel bioactives. Brands not adapting to this innovation curve risk falling behind as consumer demand for sophisticated, science-backed gut health solutions continues to escalate.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.